Charlotte Knights

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations

Life Sciences, Genetics, Molecular Biology +16

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2<i>H</i>-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

Keith Menear, Claire Adcock, Robert Boulter et al. · Journal of Medicinal Chemistry · 2008 · 586 citations · Full text

Medicine, Oncology, Pharmacology +16

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models

Lenka Oplustil O’Connor, Stuart L. Rulten, Aaron Cranston et al. · Cancer Research · 2016 · 92 citations

Medicine, Oncology, Pharmacology +16

Neutralization and Lipoprotein Binding of Lipopolysaccharides in Tolerant Rabbit Serum

H. Shaw Warren, Charlotte Knights, George R. Siber · The Journal of Infectious Diseases · 1986 · 49 citations

Life Sciences, Biochemistry, Diagnostic Microbiology +10

DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype

Céline Cano, Olivier Barbeau, C. L. Bailey et al. · Journal of Medicinal Chemistry · 2010 · 45 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13